White Paper

Could Adaptive Designs Be The Answer To Oncology Clinical Development Success?

Source: Cytel

By Yannis Jemiai

Oncology

Across all therapeutic areas, clinical development faces well-documented, critical challenges that impact the pharmaceutical industry's ability to bring new medicines to patients – but in the oncology space, these issues are particularly acute. New strategies are urgently needed to help improve the probability of clinical trial success in oncology. In this article, we examine adaptive trial designs, recently championed as a promising approach by US Food and Drug Administration (FDA) Commissioner Scott Gottlieb in his confirmation testimony to the US Congress1 Adaptive trial designs can help address the challenges encountered in anti-cancer clinical development today by saving time, resources and improving the odds of success.2

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: